Efficacy of Trastuzumab

Trastuzumab (Trastuzumab) has anti-tumor activity and is used to treat HER2-positive breast cancer. HER2 protein overexpression is observed in 20%-30% of primary breast cancers, making HER2 a useful therapeutic target for the treatment of breast cancer. Both in vitro and animal experiments have shown that trastuzumab can inhibit the proliferation of human tumor cells that overexpress HER2.

Trastuzumab is a monoclonal anti-human epidermal growth factor receptor2 protein antibody used to treat HER2-positive breast cancer, gastroesophageal cancer, and gastric cancer. Trastuzumab functions as a mediator of antibody-dependent cellular cytotoxicity, as the antibody binds to cells overexpressing HER2, leading to preferential cell death. Trastuzumab has also been shown to inhibit angiogenesis of tumor cells in vivo. Higher doses and longer dosing intervals did not show significant benefit compared with standard dosing regimens. Trastuzumab did not produce any clinically meaningful QTc interval in patients with HER2-positive solid tumors.

Trastuzumab is sold under the brand name Herceptin in China and has entered the scope of Class B medical insurance, but it may be limited to patients who meet the indications for this drug, such as patients with HER2-positive metastatic breast cancer and its adjuvant and neoadjuvant treatment or HER2-positive metastatic gastric cancer. The price is around 6,000 yuan. The original trastuzumab drug has also been launched overseas. The ingredients of domestic and foreign original drugs are basically the same. For specific prices and drug details, you can consult a medical consultant. Currently, there are no generic trastuzumab drugs on the market.